drugset

drugset / Trial / NCT00679718

A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease

NCT00679718 ↗

Phase 2 Completed 150 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of INS365 Ophthalmic Solution when applied topically in patients with moderate to severe dry eye disease.

Timeline

Start: 2000-01
Primary completion: 2000-07
Completion: 2000-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Diquafosol	Oligonucleotide (other)	—	Topical

Indications